logo BDSP

Base documentaire

  1. Ragweed immunotherapy in adult asthma.

    Article - En anglais


    Although allergen immunotherapy is effective for allergic rhinitis, its role in treating asthma is unclear.


    We examined the efficacy of immunotherapy for asthma exacerbated by seasonal ragweed exposure.

    During an observation phase, adults with asthma who were sensitive to ragweed kept daily diaries and recorded peak expiratory flow rates between July and October.

    Those who reported seasonal asthma symptoms and medication use as well as decreased peak expiratory flow were randomly assigned to receive placebo or ragweed-extract immunotherapy in doses that increased weekly for an additional two years.


    During the observation phase, the mean (rhôSE) peak expiratory flow rate measured in the morning during the three weeks representing the height of the pollination season was 454rhô20 liters per minute in the immunotherapy group and 444rhô16 liters per minute in the placebo group.

    Of the 77 patients who began the treatment phase, 64 completed one year of the study treatment and 53 completed two years.

    During the two treatment years, the mean peak expiratory flow rate was higher in the immunotherapy group (489rhô16 liters per minute, vs. 453rhô17 in the placebo group epsilonP=0.06zêta during the first year, and 480rhô12 liters per minute, vs. 461rhô13 in the placebo group epsilonP=0.03zêta during the second).

    Medication use was higher in the immunotherapy group than in the placebo group during observation and lower during the first tr...

    Mots-clés Pascal : Asthme, Allergie, Désensibilisation, Pollen, Coût, Etats Unis, Amérique du Nord, Amérique, Traitement, Adulte, Homme, Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Immunopathologie, Immunothérapie, Santé publique, Herbe à poux

    Mots-clés Pascal anglais : Asthma, Allergy, Desensitization, Pollen, Costs, United States, North America, America, Treatment, Adult, Human, Respiratory disease, Obstructive pulmonary disease, Immunopathology, Immunotherapy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0142710

    Code Inist : 002B11B. Création : 199608.